Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $243.68M | $194.52M | $154.18M | $120.70M | $110.57M | $116.63M | $5.88M | $2.73M |
| Cost of revenue | $15.05M | $9.94M | $8.11M | $6.56M | $3.65M | $2.64M | $2.08M | $598.00K |
| Gross profit | $228.63M | $184.58M | $146.07M | $114.14M | $106.91M | $113.99M | $3.80M | $2.13M |
| Gross margin | 93.8% | 94.9% | 94.7% | 94.6% | 96.7% | 97.7% | 64.6% | 78.1% |
| Research and development | $149.45M | $126.64M | $116.42M | $112.87M | $111.23M | $111.43M | $130.35M | $120.44M |
| Selling, general and administrative | $186.26M | $163.90M | $158.09M | $137.62M | $129.15M | $106.37M | $94.78M | $68.82M |
| Operating expenses | $335.71M | $290.53M | $285.63M | $259.34M | $241.19M | $218.37M | $229.83M | $193.88M |
| Operating income | −$107.08M | −$105.96M | −$139.56M | −$145.20M | −$134.28M | −$104.37M | −$226.03M | −$191.75M |
| Operating margin | -43.9% | -54.5% | -90.5% | -120.3% | -121.4% | -89.5% | -3842.7% | -7018.7% |
| EBITDA | −$106.03M | −$104.77M | −$127.00M | −$134.96M | −$132.16M | −$102.52M | −$219.97M | −$185.59M |
| Interest income | $6.66M | $6.25M | $4.33M | $6.24M | $3.90M | $5.39M | $4.68M | $3.30M |
| Interest expense | −$13.28M | −$12.94M | −$11.64M | −$11.74M | −$11.61M | −$18.12M | −$21.52M | −$23.06M |
| Income before taxes | −$155.89M | −$166.56M | −$194.76M | −$186.48M | −$181.66M | −$169.61M | −$266.24M | −$164.25M |
| Income taxes | $0 | $0 | −$120.00K | −$1.55M | $2.10M | $0 | $1.15M | — |
| Net income | −$155.89M | −$166.56M | −$194.64M | −$184.94M | −$183.76M | −$169.61M | −$267.39M | −$164.25M |
| Net margin | -64.0% | -85.6% | -126.2% | -153.2% | -166.2% | -145.4% | -4545.9% | -6012.2% |
| EPS, basic | −$0.78 | −$0.84 | −$1.00 | −$0.95 | −$0.95 | −$0.88 | −$1.40 | −$0.86 |
| EPS, diluted | −$0.78 | −$0.84 | −$1.00 | −$0.95 | −$0.95 | −$0.88 | −$1.40 | −$0.86 |
| Diluted shares | 195.79M | 194.79M | 193.59M | 191.85M | 190.52M | 190.15M | 189.50M | 188.51M |
Figures describe BridgeBio Pharma shares, not any token. As of Aug 10, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.